Get started
Author

Silke Aigner

Observed names: S Aigner, S. Aigner
Institution: Biotest (Germany)
ORCID: 0009-0003-1285-1662
Observed ORCID: 0009-0003-1285-1662
OpenAlex ID: A5016586425
CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells
1997 · Silke Aigner, Zev M. Sthoeger, et al. · Blood · 329
CD24 mediates rolling of breast carcinoma cells on P‐selectin
1998 · Silke Aigner, Carroll L. Ramos, et al. · The FASEB Journal · 289
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
2009 · Hiroshi Ikeda, Teru Hideshima, et al. · Clinical Cancer Research · 207
The L1 adhesion molecule is a cellular ligand for VLA-5.
1995 · M Ruppert, S Aigner, et al. · The Journal of Cell Biology · 146
PDF
Heat-stable antigen (CD24) as ligand for mouse P-selectin
1994 · Marei Sammar, Silke Aigner, et al. · International Immunology · 116
L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to αvβ3 integrin
1996 · Olaf Ebeling, Andreas Duczmal, et al. · European Journal of Immunology · 113
Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin
1995 · S. Aigner, M. Ruppert, et al. · International Immunology · 109
Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1
1997 · Marei Sammar, Silke Aigner, et al. · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · 53
Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
2016 · Martin König, Faiza Rharbaoui, et al. · Frontiers in Immunology · 40
PDF
Peripheral T‐cell tolerance: the contribution of permissive T‐cell migration into parenchymal tissues of the neonate
1999 · Judith Alferink, Silke Aigner, et al. · Immunological Reviews · 30
Efficacy and safety of human fibrinogen concentrate (BT524) in patients with major haemorrhage undergoing major orthopaedic or abdominal surgery (AdFIrst): a randomised, active-controlled, multicentre, partially blinded, phase 3 non-inferiority trial
2025 · Niels Rahe-Meyer, Ashok Roy, et al. · EClinicalMedicine · 15
PDF
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
2018 · Ronald F van Vollenhoven, Edward Clark Keystone, et al. · Annals of the Rheumatic Diseases · 15
Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease
2022 · Gergely Kriván, Michael Borte, et al. · Vox Sanguinis · 8
PDF
Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia
2022 · Judit Demeter, Aryan Hamed, et al. · Transfusion Medicine · 7
PDF
BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib
2010 · Chantal Zuber, Benjamin Daelken, et al. · Blood · 6
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
2022 · Gergely Kriván, Michael Borte, et al. · Journal of Clinical Immunology · 5
PDF
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.
2008 · Hiroshi Ikeda, Teru Hideshima, et al. · Blood · 5
(1125) - Selective Activation of Naturally Occurring Regulatory T Cells (Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers of Clinical Activity and Early Phase II Results in Patients with Rheumatoid Arthritis (RA)
2010 · Anatoliy Rudnev, Sukanya Ragavan, et al. · 4
Safety of a cytomegalovirus-specific hyperimmunoglobulin in the prevention of maternal–fetal transmission after primary infection—results of an open-label, single-arm, prospective trial
2026 · Karl Oliver Kagan, Martin Enders, et al. · Archives of Gynecology and Obstetrics · 3
PDF
Efficacy and safety of prophylaxis and treatment of bleeding events with a novel fibrinogen concentrate from human plasma in patients with congenital fibrinogen deficiency
2026 · Claudia Djambas Khayat, Amal El-Beshlawy, et al. · Thrombosis Research · 2
PDF
Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency
2025 · Claudia Djambas Khayat, Amal El-Beshlawy, et al. · Thrombosis and Haemostasis · 2
PDF
Phase 3 clinical trial on the prevention of maternal-fetal cytomegalovirus transmission with specific hyperimmunoglobulin could not demonstrate efficacy
2025 · Karl Oliver Kagan, Martin Enders, et al. · American Journal of Obstetrics and Gynecology · 2
PDF
Evaluation of Pharmacokinetics, Efficacy and Safety of a New Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency
2024 · Claudia Djambas Khayat, Heike Boehm, et al. · Blood · 1
PDF
226 High in vivo anti-tumor activity of the immunoconjugate BT-062 against CD138 positive solid tumors
2010 · C. Zuber, B. Dälken, et al. · European Journal of Cancer Supplements · 1
Levels of IgG subclasses 1–4 in BT595, a 10% IVIG: A sub-analysis of a clinical trial
2026 · Fabian Bohländer, Silke Aigner, et al. · PLoS ONE
PDF
Works count: 37
Citation count: 1,508
H-index: 12
I10-index: 12
Year
Topic
Type